Canada Markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
63.08+0.50 (+0.80%)
At close: 04:00PM EDT
63.00 -0.08 (-0.13%)
After hours: 07:59PM EDT
Sign in to post a message.
  • N
    NYSE
    Love it when they correct intraday then move on to recovery highs, especially on a Friday afternoon.
  • J
    Joseph
    If this finishes in the green today, that’ll be five consecutive up days. Maybe Daniel should change his name to O’Week!
  • J
    Jansen
    UP eight consecutive days in a row.
  • A
    Albertus
    7-8 year base....what a chart in the making.
  • S
    Sharbe
    The chart. We are now firmly above the 50 and 100 day moving averages. We now need to get through the 200 day at $65.53. Then maybe we can fly. If they got rid of O'Day, we would get there in one day of trading.
  • N
    NYSE
    O' what a Day it would be to get back to $65.
  • F
    Fergus Dunnion
    Fantastic article in Irish daily mail about the wonder drug Trodelvy being a life line for breast cancer sufferers
  • K
    Kjinman
    Maybe we should not have the same valuation as Merck, but we should definitely be in the same zip code. If Merck is valued at 213B down from 220B, GILD's value is safely 175B, not a penny less! Hold all shares until a price of $140!
  • d
    demetrios
    If NASH program develops, this is a 100 dollar stock easy!
  • B
    Biotech
    (EYEN) $1.70 // MC $59 million --3x Phase 3 Products including a Blockbuster with readout in Q2 =1000% UPSIDE
    https://assets.wallstreet-online.de/_media/8763/board/20220328161719-screenshot-2022-03-28-at-16-16-43-powerpoint-pres.png

    ###
  • W
    Warbaby
    Strictly a guess...Gilead had a positive presentations at the start of the liver conference?
  • S
    Sharbe
    Seems to me that Gilead only exists to make O'Day a very, very wealthy man. No other reason that I can see.
  • D
    Div
    Has anyone noticed that GILD paid 300 mill for largest licensing deal for Dragonfly in 22. No other pharma has paid any where near this so far in first 6 months of year….O’Day needs to be reigned in on these deals that never pan out anyway. BOD wake up💤💤💤
  • F
    Frank B
    Nash disease is the key multi billion dollar for the company that’s first. If Gilead figure’s out it’s a$200 stock. Many have failed but the liver is Gileads specialty
  • W
    Warbaby
    Final scorecard...4 data releases...Trodelvy 1 positive and 1 questionable...Yescarta positive...Tescarta positive. Trodelvy being explored on many different types of cancers, some easier to treat than others, some patients very sick such as those inflected with HER2 and have failed prior treatments. Not all trials will be successful was and is a given. Two things are very clear today, management over paid for Trodelvy and revenues are ramping up much slower than anyone anticipated. Up till now Remdesivir has floated the boat, will it continue?
  • N
    NYSE
    Old NYSE is going to pop his one O'Day vitamin and start pumping this stock like no stock has ever been pumped.
  • B
    Billy
    Cash flow from operations has been great. dividend coverage remains strong. It's been a long road, but I think GILD can outperforme healthcare sector form here.
  • J
    Joan
    They just featured GILD on this sites morning watchlist. (http://market-engross.club)
  • B
    Bonsack
    Just heard that GILD got alerted at (http://market-engross.club). I hope it pushes us higher!
  • S
    Sharbe
    A question for the Board. Aren't you supposed to be in a fiduciary role for shareholders? Then why is O'Day here? Isn't 3 years enough to show what a disaster he is? Come on. Our money is going into his pocket for nothing!